Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
11 Dicembre 2023 - 10:08PM
Press Release: Statement on FTC challenge to proposed license
agreement with Maze Therapeutics
Statement on FTC challenge to proposed license
agreement with Maze Therapeutics
Paris, December 11, 2023.
Sanofi is disappointed with the Federal Trade Commission’s
announcement that it is seeking a preliminary injunction against a
proposed licensing agreement between Sanofi and Maze Therapeutics.
The agreement, announced on May 1, 2023, is for MZE001, a glycogen
synthase 1 (GYS1) inhibitor program that has completed Phase 1 and
is in development for Pompe Disease, a rare, inherited and often
fatal disorder that disables the heart and skeletal muscles.
We respectfully disagree with the action by the
FTC which also delays potential advancements that could impact the
lives of patients. The Maze partnership was designed to apply
Sanofi’s resources, knowledge, and expertise to accelerate the
development of MZE001, with the hope of addressing unmet medical
needs for this devastating condition. The delay associated with a
long litigation has led Sanofi to conclude that it would not be in
the best interests of patients to contest this litigation and
Sanofi will therefore be terminating the agreement with Maze in
accordance with its terms. Sanofi remains committed to address the
Pompe patient community’s unmet needs.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.comSally
Bain | + 1 617 834 6026
| sally.bain@sanofi.comEvan Berland | +1 215
432 0234 | evan.berland@sanofi.com
Sanofi Investor Relations Eva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
Corentine.Driancourt@sanofi.com Felix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comTarik Elgoutni| + 1 617
710 3587 | Tarik.Elgoutni@sanofi.comNathalie
Pham | + 33 7 85 93 30 17 |
Nathalie.Pham@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that pandemics or other
global crises may have on us, our customers, suppliers, vendors,
and other business partners, and the financial condition of any one
of them, as well as on our employees and on the global economy as a
whole. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2022. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Apr 2023 a Apr 2024